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Summary
Whole exome sequencing of cutaneous melanoma has led to the detection of P29 mutations in 
RAC1 in 5–9% of samples, but the role of RAC1 P29 mutations in melanoma biology remains 
unclear. Using reverse phase protein array analysis to examine the changes in protein/phospho-
protein expression, we identified cyclin B1, PD-L1, Ets-1, and Syk as being selectively 
upregulated with RAC1 P29S expression and downregulated with RAC1 P29S depletion. Using 
the melanoma patient samples in TCGA, we found PD-L1 expression to be significantly increased 
in RAC1 P29S patients compared to RAC1 WT as well as other RAC1 mutants. The finding that 
PD-L1 is upregulated suggests that oncogenic RAC1 P29S may promote suppression of the 
antitumor immune response. This is a new insight into the biological function of RAC1 P29S 
mutations with potential clinical implications as PD-L1 is a candidate biomarker for increased 
benefit from treatment with anti-PD1 or anti-PD-L1 antibodies.
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Introduction
New efforts in sequencing the exomes of cutaneous melanomas led to the detection of 
recurrent P29S mutations in Ras-related C3 botulinum toxin substrate (RAC1) in 5–9% of 
samples, making this the third most frequent activating mutation in sun-exposed melanoma 
after BRAF V600 and NRAS Q61 mutations (Hodis et al., 2012; Krauthammer et al., 2012). 
RAC1 belongs to the RHO family of small GTPases, which act as molecular switches that 
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cycle between an active GTP-bound state and an inactive GDP-bound state. RAC proteins 
induce the formation of membrane ruffles and lamellipodia through their regulation of actin 
polymerization, making them essential in the maintenance of cell morphology and cell 
migration (Ridley, 2001). RAC1 also influences cell proliferation and gene transcription. 
Among the many effector proteins associated with RAC1 are scaffold proteins (Pard6 A,G; 
IQGAP1,2; Nck1; Cdc42SE1,2; IL1Rap1; Hspc121), serine/threonine kinases (Pak1-3, 
Map3K11, PrkcA), and the regulatory p85 subunit of PI3K (PIK3R1) (Bustelo et al., 2007).
The proline to serine substitution at codon 29 (RAC1 P29S) is a C>T transition (CCT>TCT), 
which is consistent with a molecular signature associated with ultraviolet radiation damage 
(Krauthammer et al., 2012). The RAC1 codon 29 is part of the switch I region and is distinct 
from the gain-of-function mutations found in RAS isoforms at codons 12 or 61, which lead 
to defective GTP hydrolysis (Davis et al., 2013). The P29S mutation in the RAC1 protein 
leads to a fast cycling GTPase, with increased inherent GDP/GTP nucleotide exchange 
(Davis et al., 2013). Clinically, melanomas with the RAC1 P29 mutation are associated with 
increased thickness, increased mitotic rate, ulceration, nodular subtype, and nodal disease at 
diagnosis (Mar et al., 2014). From a structural point of view, it is known that RAC1 
effectors use residues within the switch I and switch II regions as the major docking/
recognition sites (Bishop and Hall, 2000). Therefore, the P29S mutation in the switch I 
region may have other effects on signal transduction beyond the observed fast cycling 
phenotype. There have been limited biochemical studies showing RAC1 P29S to have 
increased binding to downstream effectors as well as enhanced migration and proliferation 
(Davis et al., 2013; Krauthammer et al., 2012).
Given the prevalence of RAC1 mutations in melanoma and the relative dearth of knowledge 
on the mechanism through which RAC1 P29S transforms murine melanocytes 
(Krauthammer et al., 2012), we examined the signaling pathways associated with RAC1 
expression. Through reverse phase protein array (RPPA) analysis, we found that cyclin B1, 
PD-L1, Ets-1, and Syk were significantly upregulated with RAC1 P29S expression and 
downregulated with RAC1 P29S depletion. Western blot and flow cytometry analyses 
revealed a robust increase in PD-L1 specifically with RAC1 P29S expression. Using the 
Skin Cutaneous Melanoma (SKCM) database in The Cancer Genome Atlas (TCGA), we 
found PD-L1 expression to be significantly increased in RAC1 P29S compared to RAC1 WT 
melanoma patients. Thus, our data provide new insight into the biological function of RAC1 
P29S mutations as being involved in suppressing the antitumor immune response. Clinically, 
immunotherapies that target the inhibitory ligand PD-L1 or its receptor PD-1 have shown 
high response rates of 30–50% in melanoma, many of which are durable (Atkins et al., 
2014; Hamid et al., 2013; Topalian et al., 2012; Weber et al., 2013; Wolchok et al., 2013). 
As PD-L1 is a candidate biomarker for increased likelihood of benefit from these therapies, 
the RAC1 P29 subset of melanoma patients may derive increased benefit.
Results
RAC1 mutations in melanoma
Previous studies have identified RAC1 mutations in 5–9% of cutaneous melanoma samples 
(Hodis et al., 2012; Krauthammer et al., 2012). In agreement with published studies, the rate 
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of RAC1 mutations was 5.5% (21/382) in the SKCM database from TCGA Research 
Network (Cerami et al., 2012; Gao et al., 2013). Of these, 47.6% of the mutations are P29S 
and 19.0% of the mutations are P29L, making a total of 66.6% of the mutations occurring at 
the P29 codon (Figure 1A). The other mutations identified are V14E, E31D, P34S, S71F, 
P87L, N92K, and P140L. Interestingly, none of these mutations occur at the Q61 or G12 
codon, which are known Ras family activating mutations seen in other cancer types. In the 
cutaneous melanoma dataset from the TCGA, we found the rate of co-existing BRAF 
mutation to be 42.9% (9/21) and that of co-existing NRAS mutation to be 33.3% (7/21) 
(Figure 1B). The rate of BRAF mutations in the entire dataset is 46.3% (177/382) and that of 
NRAS is 24.9% (95/382). Compared to all melanoma patients, those with the RAC1 
mutation have 1.37 the odds of having a co-existing NRAS mutation but only 0.87 the odds 
of having a co-existing BRAF mutation. Therefore, there is significant overlap between 
NRAS and BRAF mutations with RAC1 mutations, and the rate of co-existing NRAS 
mutation is higher than expected.
RAC1 mutants have limited effects on growth
To study the effects of RAC1 expression on cell growth independent of other transforming 
mutations, we utilized melan-a cells, an immortal murine melanocyte cell line that possesses 
characteristics of normal melanocytes (Bennett et al., 1987). We used site-directed 
mutagenesis to introduce a P29S mutation in wild-type (WT) RAC1 with an eGFP tag 
(Figure S1). The RAC1 WT construct was used as a control for RAC1 overexpression and 
RAC1 Q61L as a constitutively active form of RAC1. Western blotting showed that the 
RAC1 constructs were expressed in melan-a (Figure 2A). To determine RAC1 activity, we 
looked at p21-activated kinase 1 (Pak1), a downstream mediator of RAC1 (Bid et al., 2013). 
Expression of RAC1 increased levels of phospho-Pak1. Fluorescence staining of the actin 
cytoskeleton with phalloidin indicated that the expression of RAC1 P29S and Q61L led to 
more cells with membrane ruffling (Figures 2B and S2).
Compared to RAC1 WT, both RAC1 P29S and RAC1 Q61L have been shown to increase 
proliferation (Hodis et al., 2012; Krauthammer et al., 2012). In colony proliferation assays, 
we noted a similar increase in cell growth with RAC1 Q61L (P < 0.001) > RAC1 P29S (P = 
0.001) > RAC1 WT (P = 0.069) compared to parental cells (Figure 2C, D. We examined the 
effect of RAC1 expression on growth in soft agar, an indicator of the ability of tumor cells 
to escape the requirement for interactions with the extracellular matrix. There was no 
difference in the number of colonies that formed, but there was a significant increase in the 
average colony size with RAC1 expression compared to parental melan-a cells (Figure 2E). 
In our system, expression of RAC1 led to an increase in cell growth in both anchorage-
dependent and anchorage-independent conditions.
RAC1 mutants do not confer resistance to MEK inhibitors
Studies from other groups indicate that RAC1 P29S is a mode of resistance to RAF 
inhibitors in mutant BRAF melanoma (Watson et al., 2014). It is important to understand 
how RAC1 mutations alter the response to targeted therapies in subsets of melanomas. We 
examined the effect of RAC1 expression in response to the MEK inhibitor, trametinib. In 3D 
culture systems that mimic the dermal microenvironment of melanoma, melan-a cells were 
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resistant to the effects of trametinib, with no significant increase in apoptosis, as measured 
by levels of the early apoptotic marker annexin V (Figure 3A). The expression of RAC1, 
either wild type or mutant, did not affect the level of apoptosis induced by trametinib.
Given that melan-a cells were insensitive to trametinib, we were not able to test the 
protective effects of RAC1 mutants in cell death assays. Mutant NRAS melanoma cells have 
varied response to MEK inhibition (Solit et al., 2006; Vu and Aplin, 2014). Therefore, we 
generated two mutant NRAS cell lines with inducible expression of RAC1 WT, RAC1 P29S 
or RAC1 Q61L (Figure 3B). In 3D culture systems, the two mutant NRAS human melanoma 
cell lines, WM1346 TR and WM1361A TR, were sensitive to trametinib, as indicated by 
increased annexin V positivity following trametinib treatment (Figure 3C). Inducible 
expression of RAC1 WT, P29S, or Q61L did not significantly change the degree of 
apoptosis induced by trametinib (Figure 3C). In YUHEF cells, a melanoma cell line wild 
type for both BRAF and NRAS with an endogenous RAC1 P29S mutation, we depleted 
endogenous RAC1 by siRNA transfection (Figure 3D) to determine whether RAC1 loss 
sensitized the cells to MEK inhibition. In response to trametinib, YUHEF cells had a 23.9% 
increase in apoptosis (Figure 3E). RAC1 depletion increased apoptosis in YUHEF cells, and 
this was further enhanced by 21.8% following addition of trametinib. The similar increase in 
trametinib-induced apoptosis in the absence and presence of RAC1 depletion indicated that 
RAC1 depletion did not increase sensitivity to trametinib. In sum, RAC1 does not confer 
resistance to MEK inhibition.
PD-L1 expression is specific to RAC1 P29S signature
Next, we utilized a high-throughput antibody-based RPPA platform (Tibes et al., 2006) to 
identify proteins and signaling pathways regulated by RAC1 expression. The RPPA analysis 
utilized 218 validated antibodies. A significance analysis of microarrays (SAM) identified 
several proteins that were differentially expressed with each RAC1 construct (Figure 4A). 
With RAC1 WT expression, there were 71 proteins that were upregulated and 40 that were 
downregulated; with RAC1 P29S expression, 87 were upregulated and 38 downregulated; 
and with RAC1 Q61L expression, 17 were upregulated and 36 were downregulated. There 
were 42 different proteins and phospho-proteins that were similarly regulated with the 
expression of the RAC1 WT, RAC1 P29S, and RAC1 Q61L compared to parental melan-a 
cells (Figure 4B). KEGG pathway analysis (DAVID software) of the up- and downregulated 
proteins showed an enrichment of pathways involved in various cancers, including 
melanoma, and cell cycle regulation (Figure 4C). The enrichment of pathways involved in 
cell cycle and cancer signaling likely reflects the increase in cell growth seen with RAC1 
expression (Figure 2C–E). The majority of the up- or downregulated proteins were shared in 
common between or among RAC1 WT, RAC1 P29S, and RAC1 Q61L. However, several 
proteins were uniquely regulated, specifically 8 with RAC1 WT, 21 with RAC1 P29S, and 5 
with RAC1 Q61L (Figure 4B).
To define a protein signature specific to RAC1 P29S, we compared the changes with RAC1 
P29S overexpression in melan-a cells and the changes with RAC1 depletion in YUHEF 
melanoma cells, which harbor an endogenous RAC1 P29S mutation. SAM showed 18 
proteins that were upregulated and 72 that were downregulated with RAC1 depletion in 
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YUHEF cells (Figure 5A). Nineteen proteins were upregulated with RAC1 P29S expression 
and downregulated with RAC1 depletion, and one protein was downregulated with RAC1 
P29S expression and upregulated with RAC1 depletion (Figure 5B). Of the 20 proteins 
differentially regulated, four are part of the 21 protein subset that were uniquely changed 
with the expression of RAC1 P29S: cyclin B1, Pdcd-1L1 (aka PD-L1, CD274), Ets-1, and 
Syk (boxed in Figure 5B).
We performed Western blot analysis to validate the findings of the RPPA. We found a 
modest increase in levels of cyclin B1, Ets-1, and Syk with RAC1 expression (Figure 5C). 
The level of PD-L1 was dramatically increased with RAC1 P29S expression. To evaluate 
the levels of the proteins of interest in YUHEF cells after depletion of RAC1, we utilized an 
additional siRNA targeting RAC1 (Figure 5D). With RAC1 depletion, there were decreases 
in PD-L1, Ets-1, and Syk that correlate with the degree of RAC1 knockdown. The 
specificity of the PD-L1 antibodies used for Western blot analysis was validated with PD-L1 
knockdown in both a human melanoma cell line and melan-a cells (Figure S3A,B). We 
examined the surface expression of PD-L1 utilizing flow cytometry, after validating the 
specificity of the antibody with PD-L1 knockdown (Figure S3C). As was seen with Western 
blot analysis, surface staining of PD-L1 in melan-a cells expressing RAC1 WT and RAC1 
Q61L was similar to that of parental cells melan-a, but expression of RAC1 P29S led to a 
significant increase in surface PD-L1 expression (Figure 5E, F.
To extend our studies to human patient samples, we evaluated the mutant RAC1 subset for 
PD-L1 expression in the SKCM database in the TCGA (Cerami et al., 2012; Gao et al., 
2013). There was no significant difference in PD-L1 expression between the wild-type 
RAC1 and mutant RAC1 patients when accounting for the full spectrum of RAC1 mutations 
(P = 0.292). We next evaluated PD-L1 expression in patients with a RAC1 P29 mutation 
(Figure 5G). For the RAC1 P29S subset, we found a significant increase in PD-L1 mRNA (P 
= 0.005) compared to wild-type RAC1 patients. In the RAC1 P29L subset, we did not see an 
increase in PD-L1 expression (P = 0.824). With both exogenous expression of RAC1 P29S 
in vitro and endogenous expression of RAC1 P29S in melanoma patients, we found that 
RAC1 P29S expression is correlated with an increase in PD-L1 expression.
Discussion
In recent years, advances in DNA sequencing have led to the identification of many new 
mutations in melanomas. The current challenge lies in understanding the biological effects 
of these mutations to identify clinically significantly events. In agreement with published 
studies, the rate of RAC1 mutations was 5.5% (21/382) in the SKCM database from TCGA 
Research Network. Previously, it was found that in RAC1 mutant melanomas, the rate of co-
existing NRAS mutation (30%) is higher than expected, whereas the rate of co-existing 
BRAF mutation was only 26% (Mar et al., 2014). In the cutaneous melanoma dataset from 
the TCGA, we found the rate of co-existing BRAF mutation to be 42.9% (9/21) and that of 
co-existing NRAS mutation to be 33.3% (7/21). Thus, there is a high degree of overlap 
between melanomas with mutations in RAC1 and those with mutations in BRAF or NRAS.
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RAC1 is known to positively regulate cell proliferation, and the P29S mutant has been 
shown to enhance cell growth (Davis et al., 2013; Krauthammer et al., 2012). We found that 
RAC1 expression led to an increase in both anchorage-dependent and anchorage-
independent growth in immortalized melanocytes. Morphologically, expression of RAC1 
P29S and RAC1 Q61L led to an increase in membrane ruffling, a phenotype commonly 
attributed to RAC1 activating mutations due to their regulation of F-actin reorganization 
(Davis et al., 2013). Given the proliferative advantage conferred by RAC1 mutations, the 
role of RAC1 in response to targeted therapies has been evaluated. While some have found 
melanoma cell lines with RAC1 P29S mutation to be resistant to RAF and MEK inhibitors 
(Watson et al., 2014), others have found that RAC1 mutation status does not predict 
sensitivity to RAF or MEK inhibitors (Halaban, 2015). Given the heterogeneity of 
responses, we analyzed the response of mutant NRAS melanoma to MEK inhibitors and 
found that RAC1 expression does not decrease cell death in the presence of the MEK 
inhibitor, trametinib. Conversely, RAC1 depletion in a melanoma cell line with an 
endogenous RAC1 P29S mutation does not lead to an increase in cell death upon MEK 
inhibition.
We utilized RPPA analysis to dissect the molecular pathways regulated by RAC1 
expression. Of the 218 validated antibodies, 42 were similarly regulated with RAC1 WT, 
RAC1 P29S, and RAC1 Q61L expression. Twenty-one of the proteins were uniquely 
regulated by RAC1 P29S expression. Of these 21, four upregulated proteins (cyclin B1, PD-
L1, Ets-1, and Syk) were also downregulated by RAC1 depletion in YUHEF melanoma 
cells, which harbor an endogenous RAC1 P29S mutation. Western blot and FACS analysis 
revealed a strong increase in levels of PD-L1 with RAC1 P29S expression. PD-L1 is the 
ligand for PD-1, and the two proteins form an inhibitory receptor/ligand axis within the 
immune system. Persistent PD-1 expression on T-cells induces T-cell exhaustion and loss of 
effector function (Barber et al., 2006). PD-1 has two binding ligands, PD-L1 and PD-L2, 
with PD-L1 having a broader expression pattern (Ohaegbulam et al., 2015). Mutations in 
melanoma likely contribute to the immunogenicity of this cancer, and the expression of 
mutated antigens in melanoma cells can be recognized by tumor infiltrating lymphocytes 
(Robbins et al., 2013). Inhibition of the MEK-ERK1/2 pathway has been shown to decrease 
the production of immunosuppressive soluble factors such as IL-10, IL-6, and IL-1 in 
mutant BRAF melanoma (Khalili et al., 2012; Sumimoto et al., 2006). Additionally, BRAF 
V600E has been shown to suppress the expression of melanocyte differentiation antigens 
(MDAs) such as MART-1 and gp100 (Boni et al., 2010) and MHC-1 surface expression 
(Bradley et al., 2015), which are critical components of the immunologic response to 
melanoma. Inhibition of the ERK1/2 pathway in BRAF V600E melanoma leads to an 
increase in expression of MDAs and MHC-1 (Boni et al., 2010; Bradley et al., 2015). To the 
best of our knowledge, our observation that PD-L1 is increased with RAC1 P29S is the first 
of a role for the RAC1 P29S oncogene in modulating the immunogenicity of melanoma. The 
exact mechanism through which RAC1 P29S regulates PD-L1 expression remains to be 
elucidated.
In melanoma, PD-L1 marks a subset of patients with decreased overall survival (Hino et al., 
2010; Massi et al., 2014). Clinical trials of PD-1- or PD-L1-blocking monoclonal antibodies 
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(mAb) in melanoma patients have shown high response rates of 30–50% (Atkins et al., 
2014; Hamid et al., 2013; Topalian et al., 2012; Weber et al., 2013; Wolchok et al., 2013). 
Remarkably, these responses are durable with many lasting more than a year. Expression of 
PD-L1 by tumor cells may correlate with response to anti-PD-1 and PD-L1 therapies. In 
three Phase I studies of nivolumab, a fully human IgG4 mAb to PD-1, the relationship 
between tumor PD-L1 expression and response to therapy is unclear. Two trials showed a 
response in some PD-L1-positive patients and no response in PD-L1-negative patients 
(Brahmer et al., 2012; Topalian et al., 2012), while another did not find a correlation 
between response and PD-L1 positivity (Wolchok et al., 2013). In these three studies, PD-L1 
positivity was defined as 5% of tumor cells exhibiting membranous staining on IHC. More 
recently, a Phase I clinical trial of melanoma patients receiving pembrolizumab, a 
humanized IgG4 PD-1-blocking mAb, PD-L1 expression, as defined by PD-L1 positivity in 
1% of stained cells in IHC, was significantly associated with progression-free survival and 
response rate (Daud et al., 2014). Given the correlation between RAC1 P29S expression and 
PD-L1 expression, it would be interesting to evaluate the response to anti-PD-L1 or anti-
PD-1 therapies in this subgroup.
In summary, we show a novel role for RAC1 P29S in modulating the expression of PD-L1 
in melanoma. The expression of PD-L1 is a compensatory measure by melanomas to evade 
the immune system, which may explain the enrichment of RAC1 P29S-harboring tumor 
cells. Additionally, given the role of anti-PD-1 and PD-L1 antibodies, RAC1 P29S may be a 
useful predictor of response to such therapies.
Methods
Cell culture
WM1346 and WM1361A melanoma lines were kindly donated by Dr. Meenhard Herlyn 
(Wistar Institute, Philadelphia, PA, USA). Melan-a cells were provided by Dr. Dorothy 
Bennett (St. George’s University of London, UK). YUHEF cells were provided by Dr. Ruth 
Halaban (Yale University, New Haven, CT, USA). Melan-a cells were maintained in 
RPMI-1640 with 10% fetal bovine serum (FBS) and 200 nM TPA. YUHEF cells were 
maintained in OptiMEM media (Invitrogen, Carlsbad, CA, USA) supplemented with 5% 
FBS. WM cell lines were cultured in MCDB 153 medium containing 20% Leibovitz L-15 
medium, 2% FBS, and 0.2% sodium bicarbonate.
Cloning and stable cell line generation
RAC1 WT-eGFP and RAC1 Q61L-eGFP cDNA were purchased from Addgene 
(Cambridge, MA). RAC1 P29S-eGFP cloned from RAC1 WT-eGFP using the following 
primers for site-directed mutagenesis: forward 5′-ATATTCTCCAGAAAATGCATT-3′ and 
reverse 5′-AATGCATTTTCTGGAGAATAT-3′. All DNA constructs were sequence-
verified. Lentiviral particles and melan-a and tetracycline repressor-expressing (TR 
expressing) sublines WM1346 TR and WM1361A TR expressing RAC1 WT-eGFP and 
RAC1 P29S-eGFP and RAC1 Q61L-eGFP were generated, as previously described (Abel 
and Aplin, 2010). Transgene expression was induced with 0.1 µg/ml doxycycline in the cell 
culture medium.
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Western blot analysis
Cells lysed in sample buffer were separated by SDS-PAGE, and proteins were transferred 
electrophoretically onto Immobilon P membranes (Millipore Corp., Bedford, MA, USA). 
Membranes were blocked with phosphate-buffered saline (PBS) containing 1% bovine 
serum albumin (BSA) and 0.1% Tween-20 for 1 h and subsequently incubated with primary 
antibody overnight at 4°C. Antibodies for GFP (sc-8334), RAC1 (sc-95), PD-L1 (sc-19095), 
cyclin B1 (sc-245), Syk (sc-929), and Ets-1 (sc-55581) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA), actin (A2066) from Sigma-Aldrich (St. Louis, MO, USA), 
and PD-L1 (AF156) from R&D Systems (Minneapolis, MN, USA). Membranes were 
washed in PBS/Tween and incubated with anti-mouse or anti-rabbit IgG peroxidase 
conjugates (Calbiochem, San Diego, CA, USA) for 1 h at room temperature. Western blots 
were developed using SuperSignal chemiluminescent substrate (Pierce, Rockford, IL, USA). 
Immunoreactivity was detected and quantified using a Fluor-S Multi-Imager and Quantity-
One software (Bio-Rad, Hercules, CA, USA).
Immunofluorescence
Melanoma cells growing on glass coverslips were washed with PBS and fixed with 3.7% 
formaldehyde for 20 min. Cells were then permeabilized with 0.2% Triton X-100 for 5 min 
and nonspecific staining blocked with 1% BSA/PBS for 2 h at room temperature. Coverslips 
were then incubated with primary antibodies diluted in 1% BSA/PBS overnight at 4°C. 
After primary antibody, coverslips were washed three times with PBS before incubation 
with appropriate Alexa Fluor-conjugated secondary antibodies (Invitrogen) for 1 h at room 
temperature. For phalloidin staining, cells were incubated with phalloidin (Sigma-Aldrich) 
for 10 min at room temperature. In some instances, the coverslips were incubated with DAPI 
to visualize nuclei. Coverslips were mounted and visualized on an Eclipse Ti inverted 
microscope with NIS-Elements AR 3.00 software (Nikon, Melville, NY, USA).
Colony formation assay
Mutant NRAS cells (4 × 103) were plated per six-well plate in complete medium with or 
without inhibitors, which were replenished every 2 days. After 10 days, cells were stained 
with crystal violet in formalin, plates were imaged by scanning, and colonies were imaged 
on a Nikon Eclipse Ti inverted microscope with NIS-ELEMENTS AR 3.00 software.
3D collagen gels and apoptosis assay
Collagen gels were cast and cells were isolated and stained with annexin V-APC as 
previously described (Kaplan et al., 2012). Apoptosis was analyzed by flow cytometry on 
FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were 
analyzed by FlowJo software (Tree Star Inc., Ashland, OR, USA).
RNA interference
YUHEF cells were transfected for 4 h with chemically synthesized short interfering RNA 
(siRNA) at a final concentration of 25 nM using Oligofectamine (Invitrogen). Cells were 
harvested after a further 68 h. The RAC1 siRNAs (#6: M-003560-06 and #30: 
D-003560-30) were purchased from Dharmacon Inc. (Lafayette, CO, USA).
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RPPA analysis
Cells were lysed and proteins prepared, as previously described (Tibes et al., 2006). Lysates 
were run against 187 validated antibodies, and analyses were performed using normalized 
data. Analysis was performed with triplicate normalized RPPA data and SAM using MeV 
4.9 (Dana-Farber Cancer Institute, Boston, MA, USA). KEGG pathway analysis of up- and 
downregulated proteins with RAC1 expression was performed using DAVID (Huang da et 
al., 2009a,b).
Reagents
Trametinib (GSK11202212) was purchased from Selleck Chemicals LLC (Houston, TX, 
USA).
PD-L1 cell surface staining
Melan-a parental cells and those expressing RAC1 were harvested. Cells were washed and 
fixed in 4% paraformaldehyde for 10 minutes. Cells were then stained with anti-PD-L1 for 1 
h. Data acquisition was performed on a LSR II with FACSCalibur flow cytometer (BD 
Biosciences). Data were analyzed by FlowJo software (Tree Star Inc.). Mean fluorescence 
intensity (MFI) was determined by gating on live cells and subtracting background (isotype) 
MFI.
Statistical analysis
Statistical analyses were performed using SPSS v22.0 (IBM, Armonk, NY, USA). A P value of 
<0.05 was considered statistically significant. Tukey HSD was used to evaluate growth 
curves, and Student’s t-test was used to evaluate colony number and size in soft agar. A one-
way ANOVA analysis of PD-L1 mRNA expression levels was performed on 9 RAC1 P29S 
mutants, 4 RAC1 P29L mutants, 7 non-P29 RAC1 mutants, and 282 RAC1 WT. Log-
transformed PD-L1 expression levels of each RAC1 type were found to be normally 
distributed using Shapiro–Wilk’s test (P > 0.05). There was homogeneity of variances 
among all groups, as determined by Levene’s test of equality of variances (P = 0.343). 
Dunnett’s one-tailed multiple comparison post hoc tests were performed to determine the 
statistical significance of the RAC1 P29S samples compared to the other groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
Recent efforts in exome sequencing of cutaneous melanoma samples identified a 
recurrent RAC1 P29S mutation. We utilized an unbiased protein array to determine 
proteins regulated by RAC1 P29S and identified a correlation between PD-L1, a negative 
immune modulator, and RAC1 P29S. This finding provides novel insight into the biology 
of RAC1 P29S, with a potential role in evading the antitumor immune response. 
Additionally, RAC1 P29S melanoma patients may derive increased benefit from immune 
therapies that target PD-L1 or its receptor, PD-1.
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Figure 1. 
Characterization of RAC1 mutants in melanoma. (A) The distribution of RAC1 mutations in 
the Skin Cutaneous Melanoma (SKCM) database from the TCGA Research Network. (B) 
The distribution of mutant RAC1 melanomas with co-mutations in BRAF or NRAS.
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Figure 2. 
RAC1 expression increases growth. (A) Western blot analysis of melan-a cell lines 
expressing RAC1 WT-eGFP, RAC1 P29S-eGFP, and RAC1-Q61L-eGFP. Quantitation is 
normalized to actin control. (B) Immunofluorescence image of melan-a, melana RAC1 WT-
eGFP, melan-a RAC1 P29S-eGFP, and melan-a RAC1 Q61L-eGFP cells stained for DAPI 
(blue), phalloidin (red), and GFP (green). Scale bar = 100 µm. (C) Melan-a, melan-a RAC1 
WT, melan-a RAC1 P29S, and melan-a RAC1 Q61L cells were plated at low density and 
cultured for 1 week. Cells were stained with crystal violet, representative images shown. (D) 
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Melan-a, melan-a RAC1 WT (P = 0.069), melan-a RAC1 P29S, and melan-a RAC1 Q61L 
cell proliferation over 7 days (n = 3; errors bars, SE; **P < 0.01; *** P < 0.001). (E) Soft 
agar growth assay for melan-a, melan-a RAC1 WT, melan-a RAC1 P29S, and melan-a 
RAC1 Q61L cells. The number of colonies and size of colonies (in triplicate fields of view) 
was determined after 4 weeks (n = 3; mean ± SE; **P < 0.01). Representative 4 × images 
are shown.
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Figure 3. 
RAC1 expression does not affect sensitivity to MEK inhibition. (A) Melan-a RAC1 WT, 
melan-a RAC1 P29S, and melan-a RAC1 Q61L cells were cultured in 3D collagen and 
treated with trametinib (90 nM) for 48 h. Cells were stained with annexin V and analyzed by 
flow cytometry (n = 3; errors bars, SE). (B) WM1346 TR and WM1361A TR cells with 
tetracycline-inducible expression of RAC1 WT, RAC1 P29S, and RAC1 Q61L were treated 
with dox for 72 h. Cells were lysed and lysates analyzed by Western blot. (C) WM1346 TR 
and WM1361A TR cells with inducible expression of RAC1 WT, RAC1 P29S, and RAC1 
Q61L cells were pretreated with dox for 72 h. Cells were then cultured in 3D collagen and 
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treated as in (A). (D) YUHEF cells were transfected with non-targeting or RAC1-targeting 
siRNA, and after 72 h, cells were lysed and lysates analyzed by Western blot. (E) YUHEF 
cells were transfected as in (D), cultured in 3D collagen, and treated as in (A).
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Figure 4. 
Signaling pathways modulated by RAC1 mutants. (A) Significance analysis of microarray 
for RPPA of parental melan-a cells and melan-a cells expressing RAC1 WT, RAC1 P29S, 
and RAC1 Q61L. Expression was normalized to the mean. (B) Venn diagram depicting 
number of proteins significantly regulated in, between, and among melan-a cells expressing 
RAC1 WT, RAC1 P29S, and RAC1 Q61L. (C) Top ten KEGG pathways enriched in the 42 
proteins similarly regulated by RAC1 WT, RAC1 P29S, and RAC1 Q61L.
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Figure 5. 
Signaling pathways distinct in RAC1 P29S mutation. (A) Significance analysis of 
microarray for RPPA of YUHEF cells transfected with non-targeting siRNA or RAC1-
targeting siRNA #6. Expression was normalized to the mean. (B) Venn diagram depicting 
number of proteins significantly upregulated in melan-a RAC1 P29S and downregulated in 
YUHEF cells transfected with RAC1-targeting siRNA #6 (left) and proteins significantly 
downregulated in melan-a RAC1 P29S and upregulated in YUHEF cells transfected with 
RAC1-targeting siRNA #6 (right). Heat map of differentially regulated proteins (bottom). 
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Expression was normalized to the mean. The four boxed proteins are uniquely upregulated 
in melan-a cells expressing RAC1 P29S. (C) Western blot analysis of melan-a cells and 
melan-a cells expressing RAC1 WT, RAC1 P29S, or RAC1 Q61L. Quantitation is 
normalized to actin control. (D) Western blot analysis of YUHEF cells transfected with non-
targeting or RAC1-targeting siRNAs, #6 and #30, for 72 h. Quantitation is normalized to 
actin control. (E) Representative FACS analysis of surface PD-L1 expression on melan-a 
cells with or without RAC1 expression. (F) Mean fluorescence intensity (MFI) of surface 
PD-L1-APC on melan-a cells with or without RAC1 expression. MFI was determined by 
gating on live cells and subtracting background (isotype) MFI (n = 3; mean ± S.E.). (G) Box 
and whisker plot of log PD-L1 (CD274) mRNA in RAC1 WT, RAC1 non-P29 mutants, 
RAC1 P29S, and RAC1 P29L patients in the SKCM database of TCGA Box.
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